CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20997

MICROBIOLOGY REVIEW(S)

si on

REVIEW FOR HFD-170 OFFICE OF NEW DRUG CHEMISTRY MICROBIOLOGY STAFF MICROBIOLOGIST'S REVIEW #1 of NDA 20-997 4 August 1998

A. 1. NDA 20-997

APPLICANT: Darwin Discovery Limited
Cambridge Science Park
Milton Road
Cambridge CB4 4WE

England

- 2. PRODUCT NAMES: CHIROCAINE® (levobupivacaine inj.)
- 3. DOSAGE FORM AND ROUTE OF ADMINISTRATION:
 The product is provided in 2.5, 5.0, and 7.5 mg/mL strengths at fill volumes of 10 mL in a 10 mL vial and 30 mL in a 30 mL vial, all are single use configurations. The product is intended for infiltrative, epidural, or intrathecal administration.
- 4. METHODS OF STERILIZATION: The product is
- PHARMACOLOGICAL CATEGORY and/or PRINCIPLE INDICATION: The product is an anesthetic.
- B. 1. DATE OF INITIAL SUBMISSION: 27 April 1998
 - 2. DATE OF AMENDMENT: (none)
 - 3. RELATED DOCUMENTS: (none)
 - 4. ASSIGNED FOR REVIEW: 27 July 1998
- C. REMARKS: The drug product is sterilized, visually inspected, labeled, packaged and quality control tested at Ben Venue Laboratories, Inc., 300 Northfield Road, Bedford, OH.

D. CONCLUSIONS: The application is recommended for approval on the basis of sterility assurance.

Paul Stinavage, Ph.D. The 8/12/98